Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 75 versus NUCYNTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 75 versus NUCYNTA.
DURAGESIC-75 vs NUCYNTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Tapentadol is a centrally acting analgesic with dual mechanisms of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition.
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg/day.
None Documented
None Documented
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Terminal elimination half-life is approximately 4 hours (range 3-5 hours); no significant accumulation with repeated dosing at recommended intervals.
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Primarily renal excretion (approximately 95% of the dose is excreted in urine as tapentadol and its conjugates; <1% excreted unchanged in feces).
Category C
Category C
Opioid Analgesic
Opioid Analgesic